Evidence map›Paper›PMID 36546765›Full record

ArticleNucleic acids research2023

SigH stress response mediates killing of Mycobacterium tuberculosis by activating nitronaphthofuran prodrugs via induction of Mrx2 expression.

Laura Cioetto-Mazzabò, Francesca Boldrin, Claire Beauvineau, Martin Speth, Alberto Marina, Amine Namouchi, Greta Segafreddo, Mena Cimino, Sandrine Favre-Rochex, Seetha Balasingham and 7 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 5 countries.

Laura Cioetto-MazzabòDepartment of Molecular Medicine, University of Padova, Padova 35122, Italy.
Francesca BoldrinDepartment of Molecular Medicine, University of Padova, Padova 35122, Italy.
Claire BeauvineauChemical Library Institut Curie/CNRS, CNRS UMR9187, INSERM U1196 and CNRS UMR3666, INSERM U1193, Université Paris-Saclay, Orsay 91405, France.
Martin SpethDepartment Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo 0371, Norway.
Alberto MarinaCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio 48160 Spain.
Amine NamouchiGénétique Mycobactérienne, Institute Pasteur, Paris 75015, France.
Greta SegafreddoDepartment of Molecular Medicine, University of Padova, Padova 35122, Italy.
Mena CiminoGénétique Mycobactérienne, Institute Pasteur, Paris 75015, France.
Sandrine Favre-RochexGénétique Mycobactérienne, Institute Pasteur, Paris 75015, France.
Seetha BalasinghamDepartment of Microbiology. Oslo University Hospital, Oslo 0450, Norway.
Beatriz TrastoyCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio 48160 Spain.
Hélène Munier-LehmannDépartement de Biologie Structurale et Chimie, Institut Pasteur, CNRS UMR3523, Université de Paris, Paris 75015, France.
Gareth GriffithsDepartment Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo 0371, Norway.
Brigitte GicquelGénétique Mycobactérienne, Institute Pasteur, Paris 75015, France.
Marcelo E GuerinCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio 48160 Spain.
Riccardo ManganelliDepartment of Molecular Medicine, University of Padova, Padova 35122, Italy.
Noelia Alonso-RodríguezDepartment Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo 0371, Norway.ORCID 0000-0001-6816-7892
Institut Pasteur · FRUniversity of Padua · ITCentre National de la Recherche Scientifique · FRUniversity of Oslo · NOBioCruces Health research Institute · ESCIC bioGUNE · ESIkerbasque · ESOslo University Hospital · NO

Funding

Rationalizing glycoengineering strategies for immunotherapeutic antibodiesR01AI149297 · NIAID · EMORY UNIVERSITY · PI JEFFREY Victor RAVETCH, ERIC JOHN SUNDBERG · 2020 to 2026
$3.7M
NIAID NIH HHS R01 AI149297
6 · The paper itself

Abstract

The emergence of drug-resistant Mycobacterium tuberculosis strains highlights the need to discover anti-tuberculosis drugs with novel mechanisms of action. Here we discovered a mycobactericidal strategy based on the prodrug activation of selected chemical derivatives classified as nitronaphthofurans (nNFs) mediated by the coordinated action of the sigH and mrx2 genes. The transcription factor SigH is a key regulator of an extensive transcriptional network that responds to oxidative, nitrosative, and heat stresses in M. tuberculosis. The nNF action induced the SigH stress response which in turn induced the mrx2 overexpression. The nitroreductase Mrx2 was found to activate nNF prodrugs, killing replicating, non-replicating and intracellular forms of M. tuberculosis. Analysis of SigH DNA sequences obtained from spontaneous nNF-resistant M. tuberculosis mutants suggests disruption of SigH binding to the mrx2 promoter site and/or RNA polymerase core, likely promoting the observed loss of transcriptional control over Mrx2. Mutations found in mrx2 lead to structural defects in the thioredoxin fold of the Mrx2 protein, significantly impairing the activity of the Mrx2 enzyme against nNFs. Altogether, our work brings out the SigH/Mrx2 stress response pathway as a promising target for future drug discovery programs.

Indexed as

Anti-Bacterial AgentsMycobacterium tuberculosisProdrugsBacterial ProteinsHeat-Shock ResponsePromoter Regions, GeneticTranscription, GeneticAnti-Bacterial AgentsBacterial ProteinsProdrugs

Identifiers

PMID36546765
PMCPMC9841431
OpenAlexW4312077011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.